2019
Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d’Ivoire: A model-based analysis
Ouattara EN, MacLean RL, Danel C, Borre ED, Gabillard D, Huang M, Moh R, Paltiel AD, Eholié SP, Walensky RP, Anglaret X, Freedberg KA. Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d’Ivoire: A model-based analysis. PLOS ONE 2019, 14: e0219068. PMID: 31247009, PMCID: PMC6597104, DOI: 10.1371/journal.pone.0219068.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioImmediate ARTImmediate ART initiationART initiationBudget impactLife expectancyImmediate antiretroviral therapy initiationDecrease HIV transmissionLate ART initiationModest budget impactAntiretroviral therapy initiationMedical resource useCost-effectiveness ratioCost-effectiveness analysisTherapy initiationHIV infectionHIV transmissionCôte d'IvoireART costsART efficacySTART trialCare budgetCD4CareOutcomes
2017
Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings
Antillón M, Bilcke J, Paltiel AD, Pitzer VE. Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings. Vaccine 2017, 35: 3506-3514. PMID: 28527687, PMCID: PMC5462484, DOI: 10.1016/j.vaccine.2017.05.001.Peer-Reviewed Original ResearchConceptsRoutine infant vaccinationCost-effectiveness analysisOptimal strategyHealthcare payer perspectiveVaccine priceOne-time catchMiddle-income countriesIntervention costsPayer perspectiveInfant vaccinationDong ThapRoutine vaccinationMiddle-income settingsTyphoid transmissionRate of hospitalizationNumber of dosesDynamic modelPricesWorld Health OrganizationInvestmentLwakReturnWillingnessTyphoid feverVaccination
2016
Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies
Ouattara EN, Robine M, Eholié SP, MacLean RL, Moh R, Losina E, Gabillard D, Paltiel AD, Danel C, Walensky RP, Anglaret X, Freedberg KA. Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies. Clinical Infectious Diseases 2016, 62: 1454-1462. PMID: 26936666, PMCID: PMC4872286, DOI: 10.1093/cid/ciw117.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioAntiretroviral therapyHuman immunodeficiency virusImmunologic failureLaboratory monitoringAIDS Complications-International modelFirst-line antiretroviral therapyBudget impactSecond-line antiretroviral therapyMean CD4 countStandard of careCost-effectiveness ratioLaboratory test costsCD4 monitoringART initiationCD4 countHIV infectionVL monitoringClinical outcomesImmunodeficiency virusCôte d'IvoireMean timeLife expectancyTherapyVL strategies
2015
The Clinical Role and Cost-Effectiveness of Long-Acting Antiretroviral Therapy
Ross EL, Weinstein MC, Schackman BR, Sax PE, Paltiel AD, Walensky RP, Freedberg KA, Losina E. The Clinical Role and Cost-Effectiveness of Long-Acting Antiretroviral Therapy. Clinical Infectious Diseases 2015, 60: 1102-1110. PMID: 25583979, PMCID: PMC4366583, DOI: 10.1093/cid/ciu1159.Peer-Reviewed Original ResearchConceptsDaily ART adherenceAnnual drug costsART adherenceLA-ARTAntiretroviral therapyDrug costsART-naive patientsDaily oral ARTHIV RNA suppressionSecond-line therapyFirst-line therapyFirst-line regimensHuman immunodeficiency virusDaily ARTOverall life expectancyHIV patientsAdherent patientsAvailable regimensART failureImmunodeficiency virusClinical rolePatientsRNA suppressionTherapyAnnual cost
2014
HIV Cure Strategies: How Good Must They Be to Improve on Current Antiretroviral Therapy?
Sax PE, Sypek A, Berkowitz BK, Morris BL, Losina E, Paltiel AD, Kelly KA, Seage GR, Walensky RP, Weinstein MC, Eron J, Freedberg KA. HIV Cure Strategies: How Good Must They Be to Improve on Current Antiretroviral Therapy? PLOS ONE 2014, 9: e113031. PMID: 25397616, PMCID: PMC4232561, DOI: 10.1371/journal.pone.0113031.Peer-Reviewed Original Research
2011
Impact of obesity and knee osteoarthritis on morbidity and mortality in older Americans.
Losina E, Walensky RP, Reichmann WM, Holt HL, Gerlovin H, Solomon DH, Jordan JM, Hunter DJ, Suter LG, Weinstein AM, Paltiel AD, Katz JN. Impact of obesity and knee osteoarthritis on morbidity and mortality in older Americans. Annals Of Internal Medicine 2011, 154: 217-26. PMID: 21320937, PMCID: PMC3260464, DOI: 10.7326/0003-4819-154-4-201102150-00001.Peer-Reviewed Original ResearchProjected Survival Gains from Revising State Laws Requiring Written Opt-in Consent for HIV Testing
April MD, Chiosi JJ, Paltiel AD, Sax PE, Walensky RP. Projected Survival Gains from Revising State Laws Requiring Written Opt-in Consent for HIV Testing. Journal Of General Internal Medicine 2011, 26: 661-667. PMID: 21286837, PMCID: PMC3101973, DOI: 10.1007/s11606-011-1637-5.Peer-Reviewed Original ResearchConceptsPotential survival gainsSurvival gainHIV testingDiagnosis rateAnnual HIV incidenceProportion of HIVUndiagnosed HIV prevalenceAnnual HIV diagnosis ratesHIV diagnosis ratesHIV incidenceHIV prevalenceEarly diagnosisHIVDisease controlLYGSurveillance dataAdult personsConsentConsent methodsPersonsPatientsConsent lawsBackgroundAlthoughDesignWeObjectiveTo
2010
Routine HIV Screening in France: Clinical Impact and Cost-Effectiveness
Yazdanpanah Y, Sloan CE, Charlois-Ou C, Le Vu S, Semaille C, Costagliola D, Pillonel J, Poullié AI, Scemama O, Deuffic-Burban S, Losina E, Walensky RP, Freedberg KA, Paltiel AD. Routine HIV Screening in France: Clinical Impact and Cost-Effectiveness. PLOS ONE 2010, 5: e13132. PMID: 20976112, PMCID: PMC2956760, DOI: 10.1371/journal.pone.0013132.Peer-Reviewed Original ResearchConceptsQuality-adjusted life monthsCost-effectiveness ratioQuality-adjusted life yearsGeneral populationRoutine HIVHIV prevalenceFrequent screeningLife expectancyAnnual HIV incidenceRoutine HIV screeningUndiagnosed HIV prevalenceHigh-risk groupHIV testing behaviorsInjection drug usersFrench general populationEpidemiology of infectionHIV screeningVoluntary HIVHIV infectionHIV testingAnnual screeningHIV incidenceMean ageHIV screenClinical impact
2009
When to start antiretroviral therapy in resource-limited settings.
Walensky RP, Wolf LL, Wood R, Fofana MO, Freedberg KA, Martinson NA, Paltiel AD, Anglaret X, Weinstein MC, Losina E. When to start antiretroviral therapy in resource-limited settings. Annals Of Internal Medicine 2009, 151: 157-66. PMID: 19620143, PMCID: PMC3092478, DOI: 10.7326/0003-4819-151-3-200908040-00138.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAnti-HIV AgentsAnti-Infective AgentsCD4 Lymphocyte CountCohort StudiesComputer SimulationCost-Benefit AnalysisDecision TreesDisease ProgressionDrug Administration ScheduleHealth Care CostsHIV InfectionsHumansLife ExpectancySensitivity and SpecificitySouth AfricaTrimethoprim, Sulfamethoxazole Drug CombinationConceptsAntiretroviral therapyCD4 countLong-term survivalCells/LART initiationCells/L.ART initiation strategiesIncremental cost-effectiveness ratioSevere opportunistic diseaseDoris Duke Charitable FoundationLife expectancyCD4 count thresholdHIV treatment decisionsCost-effectiveness ratioInternational clinical trialsBase-case analysisResource-limited settingsYears of lifeCost-effectiveness analysisPerson's life expectancyObservational cohortCD4 thresholdHIV diseaseTreatment guidelinesEarly therapy
2008
Scaling Up Antiretroviral Therapy in South Africa: The Impact of Speed on Survival
Walensky RP, Wood R, Weinstein MC, Martinson NA, Losina E, Fofana MO, Goldie SJ, Divi N, Yazdanpanah Y, Wang B, Paltiel AD, Freedberg KA. Scaling Up Antiretroviral Therapy in South Africa: The Impact of Speed on Survival. The Journal Of Infectious Diseases 2008, 197: 1324-1332. PMID: 18422445, PMCID: PMC2423492, DOI: 10.1086/587184.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyEligible human immunodeficiency virusEffective antiretroviral therapyHuman immunodeficiency virusNeed of therapyHIV infectionImmunodeficiency virusPatient outcomesAdult cohortDeath rateART scaleTherapyCumulative deathsTreatment slotsDeathRapid scaleHIVPatientsCohortInfectionMortality
2007
Social costs of robbery and the cost‐effectiveness of substance abuse treatment
Basu A, Paltiel AD, Pollack HA. Social costs of robbery and the cost‐effectiveness of substance abuse treatment. Health Economics 2007, 17: 927-946. PMID: 17992708, PMCID: PMC3512566, DOI: 10.1002/hec.1305.Peer-Reviewed Original Research
2006
The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening.
Gross CP, McAvay GJ, Krumholz HM, Paltiel AD, Bhasin D, Tinetti ME. The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening. Annals Of Internal Medicine 2006, 145: 646-53. PMID: 17088577, DOI: 10.7326/0003-4819-145-9-200611070-00006.Peer-Reviewed Original ResearchConceptsChronic illnessColorectal cancerChronic conditionsLife expectancyCancer stageEarly-stage colorectal cancerPopulation-based cancer registriesPatients 67 yearsRetrospective cohort studyStage I cancerAdministrative claims dataChronic condition groupsFinal study sampleYears of ageShort life expectancyCohort studyEffect of agePatient ageI cancerCancer RegistryCancer variesHealthy patientsIndividual patientsMedicare claimsAdministrative claimsForced Expiratory Volume in 1 Second Percentage Improves the Classification of Severity Among Children With Asthma
Fuhlbrigge AL, Weiss ST, Kuntz KM, Paltiel AD. Forced Expiratory Volume in 1 Second Percentage Improves the Classification of Severity Among Children With Asthma. Pediatrics 2006, 118: e347-e355. PMID: 16864642, DOI: 10.1542/peds.2005-2962.Peer-Reviewed Original ResearchMeSH KeywordsAlbuterolAnti-Asthmatic AgentsAsthmaBronchial Provocation TestsBronchodilator AgentsBudesonideChildChild, PreschoolCohort StudiesDouble-Blind MethodEmergency Service, HospitalEthnicityFemaleFollow-Up StudiesForced Expiratory VolumeHospitalizationHumansMaleMethacholine ChlorideModels, TheoreticalMulticenter Studies as TopicNedocromilRandomized Controlled Trials as TopicRiskSeverity of Illness IndexSpirometryTreatment OutcomeConceptsSerious asthma exacerbationsImportant clinical outcomesHealth care utilizationPrebronchodilator FEV1Asthma exacerbationsAsthma symptomsExpiratory volumeCare utilizationClinical outcomesSecond percentageAsthma health statusAsthma severity classificationAsthma-related eventsChildhood Asthma Management ProgramEpisode-free daysNational Asthma EducationAsthma-related hospitalizationsPrevention Program guidelinesMean symptom scoreAsthma Management ProgramFuture adverse eventsOutcomes of interestMultivariate regression analysisPopulation of childrenClassification of severity
2005
Optimal Frequency of Cd4 Cell Count and HIV Rna Monitoring Prior to Initiation of Antiretroviral Therapy in HIV-Infected Patients
Kimmel AD, Goldie SJ, Walensky RP, Losina E, Weinstein MC, Paltiel AD, Zhang H, Freedberg KA. Optimal Frequency of Cd4 Cell Count and HIV Rna Monitoring Prior to Initiation of Antiretroviral Therapy in HIV-Infected Patients. Antiviral Therapy 2005, 10: 41-52. PMID: 15751762, DOI: 10.1177/135965350501000102.Peer-Reviewed Original ResearchConceptsCD4 cell countQuality-adjusted life yearsHIV RNA monitoringAntiretroviral therapy initiationIncremental CE ratioCell countAntiretroviral therapyTherapy initiationTreatment thresholdCD4 cell count thresholdCD4 cells/mm3Initial clinical presentationCells/mm3Log10 copies/Incremental clinical benefitLife expectancyQuality-adjusted life expectancyHIV simulation modelHypothetical clinical settingsMore frequent monitoringCost-effectiveness analysisCell count thresholdAntiretroviral initiationVirological predictorsHIV RNA
2004
A Single Measure of FEV1 Is Associated With Risk of Asthma Attacks in Long-term Follow-up
Kitch BT, Paltiel AD, Kuntz KM, Dockery DW, Schouten JP, Weiss ST, Fuhlbrigge AL. A Single Measure of FEV1 Is Associated With Risk of Asthma Attacks in Long-term Follow-up. CHEST Journal 2004, 126: 1875-1882. PMID: 15596687, DOI: 10.1378/chest.126.6.1875.Peer-Reviewed Original ResearchConceptsSubsequent asthma attacksAsthma attacksAsthma severityUS cohortNetherlands cohortUse of spirometryClinical practice guidelinesLongitudinal cohort studyAssociated shortnessObjective measuresAsthma careAsthma outcomesCohort studyCurrent smokingIndependent predictorsAdverse outcomesPractice guidelinesCohortLittle dataFEV1RiskSubjectsSeverityOutcomesSpirometry
2003
Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection
Goldie SJ, Paltiel AD, Weinstein MC, Losina E, Seage GR, Kimmel AD, Walensky RP, Sax PE, Freedberg KA. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. The American Journal Of Medicine 2003, 115: 632-641. PMID: 14656616, DOI: 10.1016/j.amjmed.2003.07.007.Peer-Reviewed Original ResearchConceptsQuality-adjusted life expectancyHuman immunodeficiency virus (HIV) infectionClinical trial cohortImmunodeficiency virus infectionAdvanced diseaseCost-effectiveness ratioAdherence interventionsAntiretroviral therapyTrial cohortEarly diseaseVirus infectionUrban cohortLife expectancyHIV ribonucleic acid levelsEffective adherence interventionsCD4 cell countCombination antiretroviral therapyVirologic failure ratesLow baseline levelsFailure rateRibonucleic acid levelsStandard careHIV infectionHealthy patientsClinical trialsAge does not limit quality of life improvement in cardiac valve surgery
Sedrakyan A, Vaccarino V, Paltiel AD, Elefteriades JA, Mattera JA, Roumanis SA, Lin Z, Krumholz HM. Age does not limit quality of life improvement in cardiac valve surgery. Journal Of The American College Of Cardiology 2003, 42: 1208-1214. PMID: 14522482, DOI: 10.1016/s0735-1097(03)00949-5.Peer-Reviewed Original ResearchConceptsMental component summaryQuality of lifeCardiac valve surgeryPhysical component summaryValve surgeryAssociation of ageValve proceduresComponent summarySF-36PCS scoresMedical Outcomes Trust Short FormPatients' QOLMitral valve proceduresAortic valve proceduresOlder patientsAortic patientsMCS scoresMitral patientsQOL benefitsHealth SurveyPatientsSurgeryStatistical significanceAgeMultiple regression analysis
2002
Lifetime Cost of HIV Care in France during the Era of Highly Active Antiretroviral Therapy
Yazdanpanah Y, Goldie SJ, Losina E, Weinstein MC, Lebrun T, Paltiel AD, Seage GR, Leblanc G, Ajana F, Kimmel AD, Zhang H, Salamon R, Mouton Y, Freedberg KA. Lifetime Cost of HIV Care in France during the Era of Highly Active Antiretroviral Therapy. Antiviral Therapy 2002, 7: 257-266. PMID: 12553480, DOI: 10.1177/135965350200700405.Peer-Reviewed Original ResearchConceptsActive antiretroviral therapyHIV infectionCD4 strataAntiretroviral therapyHIV careHIV diseaseLifetime costsHighly Active Antiretroviral TherapyHigher CD4 strataHIV Clinical CohortLowest CD4 stratumCD4 cell countEra of HAARTBurden of diseaseStage of illnessCost of careHealth policy plannersHealth care costsClinical managementSpecific AIDSClinical cohortMean costFrench patientsCare costsCell count
2001
Use of Health Services by Insurance Status Among Children With Asthma
Ortega A, Belanger K, Paltiel A, Horwitz S, Bracken M, Leaderer B. Use of Health Services by Insurance Status Among Children With Asthma. Medical Care 2001, 39: 1065-1074. PMID: 11567169, DOI: 10.1097/00005650-200110000-00004.Peer-Reviewed Original ResearchConceptsPrimary care visitsHealth care useEmergency departmentInsurance statusCare visitsAsthmatic childrenMedication useCare useAsthma-related risk factorsRoutine primary care visitsProspective cohort studyHealth care visitsHealth care utilizationChildhood asthma severityPatient-provider communicationWhite childrenMedical DictionaryNew England hospitalsRace/ethnicityAsthma specialistCohort studyMedicaid childrenAsthma severityIndependent predictorsCare utilizationIncidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts
Yazdanpanah Y, Chêne G, Losina E, Goldie S, Merchadou L, Alfandari S, Seage G, Sullivan L, Marimoutou C, Paltiel A, Salamon R, Mouton Y, Freedberg K. Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts. International Journal Of Epidemiology 2001, 30: 864-871. PMID: 11511618, DOI: 10.1093/ije/30.4.864.Peer-Reviewed Original ResearchConceptsPneumocystis carinii pneumoniaPrimary opportunistic infectionCommon opportunistic infectionOpportunistic infectionsCarinii pneumoniaToxoplasmic encephalitisCytomegalovirus infectionIncidence rateGroupe d'Epidémiologie Clinique du SIDAAIDS Reference CenterCD4 lymphocyte declineIncidence of HIVHuman immunodeficiency virusAbsence of prophylaxisHIV risk behaviorsHigh incidence rateHospital-based information systemCandida esophagitisCount declineImmunodeficiency virusLymphocyte declineAntiretroviral drugsClinical guidelinesSpecific infectionsClinical cohort